Although significant advances in hemophilia treatment have improved patient outcomes and
quality of life, one of the greatest complications in severe hemophilia A is the development of …

In hemophilia A, the most severe complication of factor VIII (FVIII) replacement therapy
involves the formation of FVIII neutralizing antibodies, also known as inhibitors, in 25% to …

Quantitative abnormalities of the von Willebrand factor–factor VIII (VWF-FVIII) complex
associate with inherited bleeding or thrombotic disorders. Receptor-mediated interactions …

Despite> 80 years of clinical experience with coagulation factor VIII (FVIII) inhibitors,
surprisingly little is known about the in vivo mechanism of this most serious complication of …

Although factor VIII (FVIII) replacement therapy can be lifesaving for patients with hemophilia
A, neutralizing alloantibodies to FVIII, known as inhibitors, develop in a significant number of …

Essentials• Treatment complications in hemophilia A: inhibitors development.• Type of FVIII
products: the latest updates on plasma‐derived or recombinant FVIII immunogenicity.• …

Background Inhibitor development in previously untreated patients (PUP s) with severe
haemophilia A is a multifactorial event. It is unknown whether paediatric vaccinations given …

In haemophilia A (HA) management, antidrug antibodies, or inhibitors, are a serious
complication that renders factor VIII (FVIII) replacement therapy ineffective, increases …

Immune responses to factor VIII remain the greatest complication in the treatment of severe
hemophilia A. Recent epidemiological evidence has highlighted that recombinant factor VIII …

Introduction: Nowadays, one of the most serious treatment complications in hemophilia A is
the formation of neutralizing antibodies against coagulation factor VIII (FVIII). These so …